Literature DB >> 12213854

Progressive onset of adrenal insufficiency and hypogonadism of pituitary origin caused by a complex genetic rearrangement within DAX-1.

Roberto Salvi1, Fulgencio Gomez, Muriel Fiaux, Daniel Schorderet, J Larry Jameson, John C Achermann, Rolf C Gaillard, François P Pralong.   

Abstract

DAX-1 [dosage-sensitive sex reversal, adrenal hypoplasia congenital (AHC) critical region on the X chromosome, gene 1] is a transcription factor expressed in the adrenal gland and at all levels of the gonadotrope axis. Inactivating mutations of DAX1 result in the X-linked form of AHC with associated hypogonadotropic hypogonadism. AHC usually reveals itself as adrenal failure in early infancy, although a wide range of phenotypic expression has been reported. We describe a patient who was diagnosed with adrenal failure at 6 wk of age, but who experienced recovery of adrenal function of several months' duration later in infancy. He subsequently failed to undergo puberty because of hypogonadotropic hypogonadism of pituitary origin, and he was also diagnosed with schizophrenia in early adulthood. Molecular genetic analyses revealed a complex rearrangement in DAX1, including a 2.2-kb deletion spanning the entire second exon and a small 27-bp insertion. The putative protein encoded by this mutated gene is 429 amino acids long. The initial 389 residues probably correspond to the wild-type DAX-1 sequence, whereas the last 40 amino acids are presumably completely unrelated, being transcribed from the intronic sequence adjacent to exon 1. In vitro functional analyses confirm the absence of repressor activity exerted by such mutant protein. These studies expand the genotypic and phenotypic spectrum of DAX-1 insufficiency in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213854     DOI: 10.1210/jc.2001-011930

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

2.  A novel mutation in DAX1 (NR0B1) causing X-linked adrenal hypoplasia congenita: clinical, hormonal and genetic analysis.

Authors:  Katherine García-Malpartida; Marcelino Gómez-Balaguer; Eva Solá-Izquierdo; M José Fuentes-Pardilla; Ana Jover-Fernández; Isabel Sanz-Ruiz; Antonio Hernández-Mijares
Journal:  Endocrine       Date:  2009-08-12       Impact factor: 3.633

Review 3.  Fetal Leydig cell origin and development.

Authors:  S L Griswold; R R Behringer
Journal:  Sex Dev       Date:  2009-04-01       Impact factor: 1.824

4.  Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience.

Authors:  Lin Lin; Wen-Xia Gu; Gokhan Ozisik; Wing S To; Catherine J Owen; J Larry Jameson; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

5.  The DAX1 mutation in a patient with hypogonadotropic hypogonadism and adrenal hypoplasia congenita causes functional disruption of induction of spermatogenesis.

Authors:  Donata Ponikwicka-Tyszko; Malgorzata Kotula-Balak; Katarzyna Jarzabek; Barbara Bilinska; Slawomir Wolczynski
Journal:  J Assist Reprod Genet       Date:  2012-05-05       Impact factor: 3.412

6.  Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years' Experience in the UK.

Authors:  Federica Buonocore; Avinaash Maharaj; Younus Qamar; Katrin Koehler; Jenifer P Suntharalingham; Li F Chan; Bruno Ferraz-de-Souza; Claire R Hughes; Lin Lin; Rathi Prasad; Jeremy Allgrove; Edward T Andrews; Charles R Buchanan; Tim D Cheetham; Elizabeth C Crowne; Justin H Davies; John W Gregory; Peter C Hindmarsh; Tony Hulse; Nils P Krone; Pratik Shah; M Guftar Shaikh; Catherine Roberts; Peter E Clayton; Mehul T Dattani; N Simon Thomas; Angela Huebner; Adrian J Clark; Louise A Metherell; John C Achermann
Journal:  J Endocr Soc       Date:  2021-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.